NASDAQ:BLFS BioLife Solutions (BLFS) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free BLFS Stock Alerts $15.14 -0.86 (-5.38%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$15.09▼$16.3950-Day Range$15.14▼$18.8252-Week Range$8.92▼$24.50Volume313,436 shsAverage Volume330,544 shsMarket Capitalization$685.84 millionP/E RatioN/ADividend YieldN/APrice Target$23.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioLife Solutions alerts: Email Address BioLife Solutions MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside54.6% Upside$23.40 Price TargetShort InterestBearish7.06% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 2 Articles This WeekInsider TradingSelling Shares$550,058 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.60) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.69 out of 5 starsMedical Sector628th out of 913 stocksElectromedical Equipment Industry11th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioLife Solutions has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.06% of the outstanding shares of BioLife Solutions have been sold short.Short Interest Ratio / Days to CoverBioLife Solutions has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in BioLife Solutions has recently increased by 5.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioLife Solutions does not currently pay a dividend.Dividend GrowthBioLife Solutions does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLFS. Previous Next 2.1 News and Social Media Coverage News SentimentBioLife Solutions has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioLife Solutions this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added BioLife Solutions to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $550,058.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of BioLife Solutions is held by insiders.Percentage Held by Institutions93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLife Solutions are expected to grow in the coming year, from ($0.60) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLife Solutions is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLife Solutions is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLife Solutions has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About BioLife Solutions Stock (NASDAQ:BLFS)BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Read More BLFS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLFS Stock News HeadlinesApril 4, 2024 | insidertrades.comInsider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells 4,000 Shares of StockApril 17, 2024 | americanbankingnews.comBioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Up 5.6% in MarchApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 4, 2024 | markets.businessinsider.comBuy Rating on BioLife Solutions: Focused Growth and Market Leadership Post-DivestitureMarch 30, 2024 | msn.comPowell: ‘No reason’ to think economy is close to recessionMarch 29, 2024 | finance.yahoo.comInvestors in BioLife Solutions (NASDAQ:BLFS) have unfortunately lost 49% over the last three yearsMarch 27, 2024 | finance.yahoo.comCorporate Insiders Are Selling These 10 Small-Cap StocksMarch 14, 2024 | finance.yahoo.comDirector Amy Duross Sells 11,200 Shares of BioLife Solutions Inc (BLFS)April 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 13, 2024 | finance.yahoo.comInsider Sell: Chief Marketing Officer Todd Berard Sells 7,508 Shares of BioLife Solutions Inc (BLFS)March 8, 2024 | finance.yahoo.comWhen Will BioLife Solutions, Inc. (NASDAQ:BLFS) Become Profitable?March 4, 2024 | finance.yahoo.comBioLife Solutions to Present at TD Cowen and Key Bank Investor ConferencesMarch 2, 2024 | finance.yahoo.comBioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2024 Earnings Call TranscriptMarch 1, 2024 | finanznachrichten.deBioLife Solutions, Inc.: BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Chimerix (CMRX)March 1, 2024 | finance.yahoo.comQ4 2023 BioLife Solutions Inc Earnings CallFebruary 29, 2024 | benzinga.comRecap: BioLife Solns Q4 EarningsFebruary 29, 2024 | prnewswire.comBioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | msn.comBioLife Solutions Q4 2023 Earnings PreviewFebruary 28, 2024 | benzinga.comEarnings Preview For BioLife SolnsFebruary 28, 2024 | markets.businessinsider.comHere's what to expect from Biolife Solutions's earningsFebruary 25, 2024 | msn.comPeter Thiel resigns from AbCellera board for personal reasonsFebruary 21, 2024 | finance.yahoo.comBLFS Jul 2024 12.500 callFebruary 20, 2024 | finance.yahoo.comBioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024February 20, 2024 | prnewswire.comBioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024February 18, 2024 | finance.yahoo.comBLFS Mar 2024 25.000 callFebruary 17, 2024 | finance.yahoo.comShould You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?See More Headlines Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/18/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:BLFS CUSIPN/A CIK834365 Webwww.biolifesolutions.com Phone(425) 402-1400Fax425-402-1433Employees409Year FoundedN/APrice Target and Rating Average Stock Price Target$23.40 High Stock Price Target$25.00 Low Stock Price Target$22.00 Potential Upside/Downside+54.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,430,000.00 Net Margins-46.37% Pretax Margin-46.25% Return on Equity-13.36% Return on Assets-10.83% Debt Debt-to-Equity Ratio0.06 Current Ratio2.86 Quick Ratio1.83 Sales & Book Value Annual Sales$143.27 million Price / Sales4.79 Cash FlowN/A Price / Cash FlowN/A Book Value$7.67 per share Price / Book1.97Miscellaneous Outstanding Shares45,300,000Free Float44,077,000Market Cap$685.84 million OptionableOptionable Beta1.67 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Roderick de Greef (Age 64)CEO & Chairman Comp: $1.63MMr. Troy Wichterman (Age 39)Chief Financial Officer Comp: $485.2kMs. Karen Foster (Age 64)Chief Quality & Operations Officer Comp: $395.2kDr. Aby J. Mathew Ph.D. (Age 52)Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer Comp: $448.2kMr. Michael P. Rice (Age 61)Consultant Comp: $1.3MMr. Todd Berard (Age 55)Chief Marketing Officer Comp: $286.49kMs. Sarah Aebersold J.D. (Age 47)Chief Human Resources Officer Mr. Garrie Richardson B.Sc. (Age 51)M.B.A., Chief Revenue Officer More ExecutivesKey CompetitorsZynexNASDAQ:ZYXINatus MedicalNASDAQ:NTUSAxoGenNASDAQ:AXGNEdap TmsNASDAQ:EDAPSoleno TherapeuticsNASDAQ:SLNOView All CompetitorsInsiders & InstitutionsRegister Financial Advisors LLCBought 5,200 shares on 4/16/2024Ownership: 0.011%Sarah AebersoldSold 4,000 sharesTotal: $70,600.00 ($17.65/share)Aby J MathewSold 454 sharesTotal: $8,167.46 ($17.99/share)Karen A FosterSold 395 sharesTotal: $7,106.05 ($17.99/share)Todd BerardSold 515 sharesTotal: $9,264.85 ($17.99/share)View All Insider TransactionsView All Institutional Transactions BLFS Stock Analysis - Frequently Asked Questions Should I buy or sell BioLife Solutions stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLFS shares. View BLFS analyst ratings or view top-rated stocks. What is BioLife Solutions' stock price target for 2024? 4 Wall Street analysts have issued 1 year price targets for BioLife Solutions' stock. Their BLFS share price targets range from $22.00 to $25.00. On average, they predict the company's share price to reach $23.40 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price. View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts. How have BLFS shares performed in 2024? BioLife Solutions' stock was trading at $16.25 on January 1st, 2024. Since then, BLFS stock has decreased by 6.8% and is now trading at $15.14. View the best growth stocks for 2024 here. Are investors shorting BioLife Solutions? BioLife Solutions saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,200,000 shares, an increase of 5.6% from the March 15th total of 3,030,000 shares. Based on an average daily volume of 412,500 shares, the short-interest ratio is currently 7.8 days. View BioLife Solutions' Short Interest. When is BioLife Solutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BLFS earnings forecast. How were BioLife Solutions' earnings last quarter? BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings data on Thursday, February, 29th. The medical equipment provider reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. The medical equipment provider earned $32.73 million during the quarter, compared to the consensus estimate of $32.70 million. BioLife Solutions had a negative trailing twelve-month return on equity of 13.36% and a negative net margin of 46.37%. What guidance has BioLife Solutions issued on next quarter's earnings? BioLife Solutions issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $95.5 million-$100.0 million, compared to the consensus revenue estimate of $121.4 million. What is Mike Rice's approval rating as BioLife Solutions' CEO? 14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend. What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM). Who are BioLife Solutions' major shareholders? BioLife Solutions' stock is owned by a variety of institutional and retail investors. Top institutional investors include Register Financial Advisors LLC (0.01%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard and Troy Wichterman. View institutional ownership trends. How do I buy shares of BioLife Solutions? Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLFS) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profits[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe “Perfect Storm” for GoldGold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressYour Money is Not SafeAmerican AlternativeUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLife Solutions, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.